Market Place
Sourcing Support
Corcept’s Relacorilant Ph 3 Shows Cardiometabolic Improvements
16 Dec 2024 //
BUSINESSWIRE
Corcept`s GRACE Relacorilant Hypercortisolism Phase 3 Data Presented
03 Jun 2024 //
GLOBENEWSWIRE
Corcept: GRACE Trial Met Primary Endpoint In Cushing`s Syndrome
28 May 2024 //
GLOBENEWSWIRE
Corcept Completes Enrollment in Pivotal Ph 3 Trial of Relacorilant
08 Apr 2024 //
GLOBENEWSWIRE
Corcept Completes Enrollment in Ph 3 Trial of Relacorilant in ACS
01 Apr 2024 //
GLOBENEWSWIRE
Corcept Therapeutics to Start PIII Trial of Relacorilant Plus Nab-Paclitaxel
06 Jun 2022 //
GLOBENEWSWIRE
Relacorilant Plus Nab-Paclitaxel Extends Survival in Women with Ovarian Cancer
30 Mar 2022 //
GLOBENEWSWIRE
Positive Results Presented at ESMO 2021 From Phase 2 Trial of Relacorilant
17 Sep 2021 //
GLOBENEWSWIRE
Corcept to present +ve Results From PII Trial of Relacorilant in Ovarian Cancer
09 Sep 2021 //
GLOBENEWSWIRE
Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel
30 Jun 2020 //
GLOBENEWSWIRE
Corcept Therapeutics Announces +ve Relacorilant Data at ASCO
04 Jun 2018 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.